Nath Bio-Genes Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
For the nine months, sales was INR 2,563.76 million compared to INR 2,511.51 million a year ago. Revenue was INR 2,563.76 million compared to INR 2,511.51 million a year ago. Net income was INR 335.75 million compared to INR 489.5 million a year ago. Basic earnings per share from continuing operations was INR 17.67 compared to INR 25.76 a year ago. Diluted earnings per share from continuing operations was INR 17.67 compared to INR 25.76 a year ago.